EVALUACIÓN DE EFICACIA Y TOXICIDAD DE LA TERAPIA ANTIFÚNGICA CON VORICONAZOL EN BASE A ESTUDIOS FARMACOGENÉTICOS Y ANÁLISIS FARMACOCINÉTICOS-FARMACODINÁMICOS.

Article. 10.1016/j.thromres.2018.12.027. 2019

Benefits of Ehl Factor VIII Replacement Therapy in Hemophilia: Observations on Coverage, Physical Activity and Phisiotherapy

Querol, Felipe; (...); Bonanad Boix, Santiago

Meeting Abstract. 10.1182/blood-2019-125651. 2019

Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study.

Fernandez Rivera C; (...); Hernandez D

Article. 10.1111/ctr.14550. 2022

Breakthrough invasive fungal disease in high-risk hematologic malignancies in children: a single-center experience

Garcia-Robles, AA; (...); Fernandez-Navarro, JM

Meeting Abstract. 2017

Classification of antineoplastic drug-induced tissue damage: a Consensus of the Spanish Oncology Pharmacy Group

Albert-Mari, A; (...); Diaz-Carrasco, MS

Article. 10.7399/fh.11625. 2021

Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients

Article. 10.1016/j.thromres.2021.07.009. 2021

Clinical pharmacy services: from cost-effectiveness analysis to a productivity indicators model

Nogueras, A; (...); Calleja, MA

Letter. 10.1136/ejhpharm-2019-001905. 2019

CLINICAL VALIDATION OF THE SPECIFIC POPULATION MODEL OF FACTOR VIII/FVW PLASMA USING WAPPS-HEMO

Megias Vericat, J. E.; (...); Poveda, A. J. L.

Meeting Abstract. 2019

Clinical, pharmacokinetic and economic analysis of the first switch to an extended half-life factor IX (albutrepenonacog alfa, rFIX-FP) in Spain.

Rodríguez López M; (...); Bonanad S

Article. 10.1136/bcr-2019-234142. 2020

Collaborative model of home delivery program in haemophilia through an association of patients

Megias-Vericat, JE; (...); Bonanad, S

Meeting Abstract. 2018

Common Genetic Variants in ABO and CLEC4M Modulate the Pharmacokinetics of Recombinant FVIII in Severe Hemophilia A Patients.

Garcia-Martínez I; (...); Vidal F

Article. 10.1055/s-0040-1714214. 2020

Comparison of pharmacokinetic estimates using generic and specific population pharmacokinetic models of plasma-derived factor VIII/VWF using WAPPS-Hemo

Meeting Abstract. 2020

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano JB; (...); Soto-Ortega I

Article. 10.1016/j.farma.2023.01.003. 2023

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia.

Montoro-Ronsano, Jose Bruno; (...); Soto-Ortega, Inmaculada

Article. 10.1016/j.farma.2023.04.002. 2023

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.

Chelle P; (...); Edginton A

Article. 10.1007/s10928-019-09647-2. 2019

COST MINIMIZATION ANALYSIS OF RITUXIMAB BIOSIMILAR VERSUS REFERENCE RITUXIMAB IN THE TREATMENT OF FOLLICULAR LYMPHOMA

Gironella, M.; (...); Oyaguez, I

Meeting Abstract. 2019

COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN

Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.

Meeting Abstract. 2024

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025

Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.

Poveda JL; (...); Torres C

Article. 10.1080/14737167.2019.1635014. 2020

COST-EFFECTIVENESS OF CLADRIBINE TABLETS AND FINGOLIMOD IN THE TREATMENT OF REMITTING MULTIPLE SCLEROSIS WITH HIGH DISEASE ACTIVITY IN SPAIN

Trillo, JL; (...); Torres, C

Meeting Abstract. 10.1016/j.jval.2018.09.2029. 2018

COSTS OF THE MANAGEMENT OF HEMOPHILIA A WITH INHIBITORS IN SPAIN

Bonanad, S; (...); Gonzalez-Dominguez, A

Meeting Abstract. 2020

Costs of the management of hemophilia A with inhibitors in Spain

Bonanad, S; (...); Gonzalez-Dominguez, A

Article. 10.33393/grhta.2021.2234. 2021

Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform

Chelle, P; (...); Edginton, AN

Meeting Abstract. 10.1182/blood-2018-99-115308. 2018

Cross-sectional comparative study of pharmacokinetics and efficacy between sucrose-formulated recombinant factor VIII (Kogenate (R)) and BAY 81-8973 (KovaltryA (R)) in patients with severe or moderate haemophilia A in prophylaxis

Letter. 10.1111/hae.13733. 2019

Cross-Sectional Comparative Study of PK-Guided Switch between Standard Half-Life and Extended Half-Life Factor VIII Products

Eduardo Megias, Juan; (...); Iorio, Alfonso

Meeting Abstract. 10.1182/blood-2019-127946. 2019

Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.

Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL

Editorial Material. 10.1016/j.farma.2024.08.001. 2024

Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group

Palanques-Pastor, Tomas; (...); Montesinos, Pau

Article. 10.1080/10428194.2021.1948031. 2021

Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review

Review. 10.1080/17512433.2019.1573668. 2019

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project

Blade, J; (...); Lizan, L

Article. 10.1136/bmjopen-2017-018850. 2018

Design and rationale for a real-world prospective, multicenter registry of myocardial revascularization failure and secondary revascularization: The REVASEC study.

Salinas P; (...); Escaned J

Article. 10.1016/j.carrev.2021.11.015. 2021

Determining the value contribution of emicizumab (Hemlibra (R)) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis

Alvarez-Roman, MT; (...); Badia, X

Article. 10.1177/2284240319880534. 2019

DETERMINING THE VALUE OF EMICIZUMAB FOR THE PROPHYLAXIS OF SEVERE HAEMOPHILIA A PATIENTS WITHOUT INHIBITORS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

Alvarez, E.; (...); Badia, F. J.

Meeting Abstract. 2019

Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.

Abad, Maria Reyes; (...); Gil, Alicia

Article. 10.33393/grhta.2024.3041. 2024

Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis

Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther

Article. 10.1002/jvc2.275. 2024

Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024

DEVELOPMENT AND VALIDATION OF A MCDA FRAMEWORK FOR EVALUATION AND DECISION-MAKING OF ORPHAN DRUGS IN SPAIN

Poveda, J. L.; (...); Vitoria, I

Meeting Abstract. 2019

Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate ): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.

Chelle P; (...); Iorio A

Article. 10.1007/s40262-019-00809-6. 2020

Development and validation of an MCDA framework for evaluation and decision-making of orphan drugs in Spain

Badia, X; (...); Poved, JL

Article. 10.1080/21678707.2019.1652163. 2019

DIAGNOSIS AND MANAGEMENT OF HEMARTHROSIS AND HAEMOPHILIC ARTHROPATHY USING UNIFIED CLINICAL AND ULTRASOUND CRITERIA: PRELIMINARY RESULTS

Chimeno-Hernandez, A; (...); Querol, F

Meeting Abstract. 2021

Differences in ex-vivo Chemosensitivity to Anthracyclines in First Line Acute Myeloid Leukemia

Megias-Vericat, JE; (...); Spanish PETHEMA Grp

Article. 10.4084/MJHID.2019.016. 2019

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/17512433.2023.2174523. 2023

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Review. 10.1007/s00277-020-04186-0. 2020

Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan

Ribera, E; (...); Hernandez-Novoa, B

Article. 10.1016/j.eimc.2016.11.015. 2018

Efecto de la adición de fortificantes y de módulo de proteínas en la osmolalidad de la leche materna donada.

Torres Martínez E; (...); Vento M

Article. 10.1016/j.anpedi.2020.03.009. 2020

Effect of monitoring daily physical activity on quality of life in adult patients with haemophilic arthropathy

Perez-Alenda, Sofia; (...); Carrasco, Juan J.

Meeting Abstract. 2018

Effectiveness of Caplacizumab Nanobody in Acquired Thrombotic Thrombocytopenic Purpura Refractory to Conventional Treatment

Palanques-Pastor T; (...); Poveda Andrés JL

Article. 10.1159/000517813. 2021

eLearning of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Megias-Vericat, JE

Meeting Abstract. 2018

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.

Solana-Altabella, Antonio; (...); Montesinos, Pau

Article. 10.1080/14728214.2021.2009800. 2022

Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group

Fernandez-Cooke, E; (...); KAWA-RACE Study Grp

Article. 10.1371/journal.pone.0215665. 2019

EVALUATING REAL LIFE CRITERIA THAT COULD DRIVE PRICING & REIMBURSEMENT (P&R) APPROVAL OF ORPHAN DRUGS (ODS) IN SPAIN

Badia, F. J.; (...); Shepherd, J.

Meeting Abstract. 2019

Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.

Boluda B; (...); Montesinos P

Article. 10.1080/10428194.2021.1938031. 2021

Exploratory analysis for the implementation of antineoplastic logarithmic dose banding

Albert-Mari, A; (...); Poveda-Andres, JL

Article. 10.1007/s11096-018-0714-9. 2018

EXTENDED MULTICRITERIA DECISION ANALYSIS IN DIABETIC MACULAR EDEMA. MULTIDEX-EMD EXTENSION STUDY

F, de Andres-Nogales; (...); Martinez, M.

Meeting Abstract. 2019

Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.1002/jca.21901. 2021

Extravasation of monoclonal antibodies commonly used in oncology: Classification, management and the role of the pharmacist.

Bauters T, Clottens N, Albert-Marí MA

Article. 10.1177/10781552231178674. 2023

Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease

Beltran, B; (...); Nos, P

Article. 10.1159/000492626. 2019

Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report

Fernandez-Sanchez, M; (...); Poveda-Andres, JL

Article. 10.1002/bdr2.1942. 2021

GEDEFO-SEFH management of antineoplastic extravasations survey results.

Jiménez-Pulido I; (...); Díaz-Carrasco MS

Article. 10.1177/10781552231167873. 2023

Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.

Plaza J; (...); Moret-Tatay I

Article. 10.3390/ijms25073717. 2024

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

Ballesta-López O; (...); Montesinos P

Review. 10.2217/fon-2020-0700. 2020

Guide to Good Humanization Practices in Patients with Rare Diseases. who vadis

Poveda Andres, Jose Luis

Editorial Material. 2022

Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12568. 2017

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study

Valero-Garcia, S; (...); Spanish Hosp Pharmacy Units

Article. 10.7399/fh.10935. 2018

Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella, Antonio; (...); Martinez-Cuadron, David

Article. 10.3390/cancers14081921. 2022

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

Solana-Altabella A; (...); Montesinos P

Article. 10.1111/ejh.13604. 2021

High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients despite thrombo-prophylaxis.

El-Qutob D; (...); Carrera-Hueso FJ

Article. 10.1016/j.hrtlng.2022.02.003. 2022

Hospital pharmacy initiatives for improving the management of patients with congenital coagulopathies

Bruno Montoro-Ronsano, Jose; (...); Alberto Vella, Vincenzo

Article. 10.7399/fh.11729. 2022

Hospitalization budget impact during the COVID-19 pandemic in Spain.

Carrera-Hueso, F. J.; (...); Crespo-Palomo, C.

Article. 10.1186/s13561-021-00340-0. 2021

How can artificial intelligence optimize value-based contracting?

Poveda, Jose Luis; (...); Medrano, Ignacio H.

Letter. 10.1186/s40545-022-00475-3. 2022

IDH1-mutated relapsed or refractory AML: current challenges and future prospects

Review. 10.2147/BLCTT.S177913. 2019

Impact of ABC single nucleotide polymorphisms upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2016.1231405. 2017

Impact of an antimicrobial stewardship program on critical haematological patients.

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.7399/fh.2017.41.4.10709. 2017

Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.

Article. 10.1080/10428194.2020.1839650. 2020

Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1038/tpj.2017.19. 2018

Impact of novel polymorphisms related to cytotoxicity of cytarabine in the induction treatment of acute myeloid leukemia

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1097/FPC.0000000000000286. 2017

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019

Badia X; (...); Hernández C

Article. 10.1186/s13023-020-01507-4. 2020

Impact of voriconazole plasma concentrations on treatment response in critically ill patients

Ruiz, J; (...); Ramirez, P

Article. 10.1111/jcpt.12817. 2019

Implementation and results of a risk-sharing scheme for enzyme replacement therapy in lysosomal storage diseases

Edo-Solsona, MD, Vitoria-Minana, I, Poveda-Andres, JL

Article. 10.7399/fh.11262. 2020

Implication of Haemodiafiltration Flow Rate on Amikacin Pharmacokinetic Parameters in Critically Ill Patients

Ruiz-Ramos, J; (...); Ramirez, P

Article. 10.1159/000478969. 2018

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

Individualization of prophylaxis with recombinant factor VIII in severe or moderate hemophilia A

Vericat, JEM; (...); Bonanad, S

Meeting Abstract. 2018

Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy

Bastida, G; (...); Nos, P

Meeting Abstract. 10.1093/ecco-jcc/jjy222.581. 2019

Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment

Megias-Vericat, JE; (...); Aliño SF

Article. 10.1080/10428194.2017.1323267. 2017

Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia.

Ruiz J; (...); Poveda JL

Article. 10.23736/S0026-4946.18.04978-2. 2018

Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.

Article. 10.1097/FPC.0000000000000431. 2021

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

Walker, Andrew; (...); Nakashima, Lynne

Article. 10.1177/10781552221090199. 2022

Intraperitoneal vancomycin in neonates during peritoneal dialysis: A case report

Company-Albir, MJ; (...); Poveda, JL

Article. 10.1111/jcpt.12842. 2019

Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol.

Solana-Altabella A; (...); Poveda JL

Article. 10.1177/1078155220904410. 2020

Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19

Palanques-Pastor, T, Lopez-Briz, E, Andres, JLP

Article. 10.1136/ejhpharm-2020-002322. 2020

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.

Pozo-Rosich P; (...); Irimia P

Article. 10.1186/s10194-024-01747-w. 2024

Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.

Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula

Article. 10.3390/antibiotics13080706. 2024

Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results.

Megías-Vericat JE; (...); Poveda-Andrés JL

Article. 2021

Manipulación de fármacos para su administración por gastrostomía endoscópica percutánea en pacientes con esclerosis lateral amiotrófica y nutrición enteral.

Vázquez Polo A; (...); Vázquez Costa JF

Article. 10.20960/nh.03946. 2022

Matching-Adjusted Indirect Comparison of Efficacy and Consumption of rVIII-SingleChain Versus Two Recombinant FVIII Products Used for Prophylactic Treatment of Adults/Adolescents with Severe Haemophilia A

Bonanad, S; (...); Santos, S

Article. 10.1007/s12325-021-01853-0. 2021

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches.

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Article. 10.3390/cancers14030596. 2022

Metyrapone as treatment in the neonatal McCune-Albright syndrome

de Mingo, Carmen; (...); Garcia-Robles, Ana

Article. 10.1515/jpem-2020-0036. 2020

Monitoring coagulation factors during surgery. A systematic review

Eduardo Megias-Vericat, Juan; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11766. 2021

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH).

Valero-García S; (...); Delgado-Sánchez O

Article. 10.7399/fh.11655. 2021

Monitoring the quality of the hospital pharmacoterapeutic process by sentinel patient program.

Fernandez-Megia, MJ; (...); Poveda Andrés JL

Article. 10.7399/fh.10793. 2018

Multi-Omic Approaches to Breast Cancer Metabolic Phenotyping: Applications in Diagnosis, Prognosis, and the Development of Novel Treatments

Gomez-Cebrian, N; (...); Pineda-Lucena, A

Review. 10.3390/cancers13184544. 2021

National Survey of the SEFH-2019: portfolio of services, healthcare activity, teaching and research in Hospital Pharmacy Services in Spain (vol 45, pg 32, 2021)

Perez-Encinas, Montserrat; (...); Angel Calleja-Hernandez, Miguel

Correction. 10.7399/fh.11740. 2021

National Survey on the Use of Mobile Applications in Patients with Hemophilia and Other Coagulopathies

Eduardo Megias, Juan; (...); Poveda Andres, Jose Luis

Meeting Abstract. 10.1182/blood-2022-169938. 2022

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus

Solana-Altabella, Antonio; (...); Poveda-Andres, Jose Luis

Article. 10.1097/MD.0000000000032208. 2022

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain.

Poveda JL; (...); Badia X

Article. 10.1186/s13023-022-02610-4. 2023

Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes

Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor

Review. 10.3390/biology12091159. 2023

Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice

Bonanad, S; (...); Poveda, JL

Meeting Abstract. 2018

OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT

Flores-Moreno, S.; (...); Gil, A.

Meeting Abstract. 2024

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol

Garcia-Robles, Ana; (...); Carrascosa, MA

Article. 10.3389/fped.2020.00372. 2020

Paracetamol vs. Ibuprofen in Preterm Infants With Hemodynamically Significant Patent Ductus Arteriosus: A Non-inferiority Randomized Clinical Trial Protocol (vol 8, 372, 2020)

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Correction. 10.3389/fped.2021.834454. 2022

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project

Morillo-Verdugo, R; (...); Diaz-Olmo, J

Article. 10.7399/fh.11719. 2021

Patient and health practitioner perceptions about the role of hospital pharmacists along the care continuum: the Fharmaconectados Project.

Morillo-Verdugo R; (...); Díaz-Olmo J

Article. 2021

Pharmaceutical care to hospital outpatients during the COVID-19 pandemic. Telepharmacy

Margusino-Framiñán L; (...); Morillo-Verdugo R

Article. 10.7399/fh.11498. 2020

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

Pharmacogenetics of Metabolic Genes of Anthracyclines in Acute Myeloid Leukemia

Review. 10.2174/1389200218666171101124931. 2018

Pharmacometabolomics by NMR in Oncology: A Systematic Review.

Gómez-Cebrián N; (...); Pineda-Lucena A

Article. 10.3390/ph14101015. 2021

Pharmacotherapeutic management of advanced therapy medicinal products

Luis Poveda-Andres, Jose; (...); Valero-Garcia, Silvia

Article. 10.7399/fh.13036. 2022

Pilot evaluation of home delivery programme in haemophilia

Megias-Vericat, JE; (...); Poveda-Andres, JL

Article. 10.1111/jcpt.12718. 2018

PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS

Vericat, JEM; (...); Iorio, A

Meeting Abstract. 2020

PK-guided switch from standard half-life to extended half-life factor VIII products

Megias-Vericat, JE; (...); Iorio, Alfonso

Meeting Abstract. 2020

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants

Jacqz-Aigrain, E; (...); Zhao, W

Article. 10.1093/jac/dkz158. 2019

Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a decontamination process

Valero, S; (...); Poveda, JL

Article. 10.1016/j.yrtph.2018.03.001. 2018

Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?

Review. 10.1080/17474086.2020.1818559. 2020

PRELIMINAR STUDY OF THERAPY ADHERENCE CONTROLLED BY PRESCRIPTION OF MEDICATION AND SELF-PERCEPTION ADHERENCE OF INFLAMMATORY CHRONIC DISEASE PATIENTS

Garcia, EG; (...); Ivorra, JAR

Meeting Abstract. 10.1136/annrheumdis-2019-eular.5937. 2019

Preparación y administración de perfusiones de insulina en neonatología: Encuesta nacional.

García-Robles A; (...); Aguar-Carrascosa M

Letter. 10.1016/j.anpedi.2020.06.008. 2021

Preparation and administration of insulin infusions in neonatology: A national survey.

Garcia-Robles, Ana; (...); Aguar Carrascosa, Marta

Article. 10.1016/j.anpede.2020.06.015. 2021

Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services

Company Albir MJ, Poveda Andrés JL, Edo Solsona MD

Article. 10.1016/j.farma.2023.06.0131130. 2024

Proactive therapeutic drug monitoring and pharmacogenetic analysis in inflammatory bowel disease: A systematic review

Ballesta-Lopez, Octavio; (...); Luis Poveda-Andres, Jose

Review. 10.7399/fh.11780. 2021

Prostaglandin Injection After Arterial Compromise Related to Hyaluronic Acid Filler

Letter. 10.1097/DSS.0000000000001046. 2017

Quality of electronic treatment records and adherence to prophylaxis in haemophilia and von Willebrand disease: Systematic assessments from an electronic diary.

Tiede A; (...); Oldenburg J

Article. 10.1111/hae.14178. 2020

Quantification of physical activity in adult patients with haemophilic arthropathy in prophylaxis treatment using a fitness tracker

Perez-Alenda, S; (...); Querol, F

Letter. 10.1111/hae.13388. 2018

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients

Chelle, P; (...); Edginton, A

Meeting Abstract. 2018

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.

Chelle P; (...); Edginton A

Article. 10.1007/s10928-019-09637-4. 2019

Safety and Effectiveness of Progressive Moderate-to-Vigorous Intensity Elastic Resistance Training on Physical Function and Pain in People With Hemophilia.

Calatayud J; (...); Casaña J

Article. 10.1093/ptj/pzaa106. 2020

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review

Review. 10.1007/s00277-018-3304-y. 2018

Salvage therapy with topical posaconazole in lung transplant recipients with invasive Scedosporium infection.

Sole, A; (...); Peman, J

Article. 10.1111/ajt.14580. 2018

SEFH National Survey-2019: general characteristics, staffing, material resources and information systems in Spain's hospital pharmacy departments.

Pérez-Encinas M; (...); Calleja-Hernández MÁ

Article. 10.7399/fh.11565. 2020

Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice

Aguas Peris M; (...); Nos, P

Article. 10.1097/MIB.0000000000001182. 2017

SMPTall man lettering application in medication information systems as a quality and safety strategy in hospital organization

Iglesias Gomez, Ruben; (...); Poveda Andres, Jose Luis

Article. 10.1111/jcpt.13703. 2022

SWITCH ANALYSIS GUIDED BY PHARMACOKINETICS FROM FACTORS VIII OF STANDARD HALF LIFE TO EXTENDED HALF LIFE FACTORS

Megias Vericat, J. E.; (...); Poveda, A. J. L.

Meeting Abstract. 2019

Systematic Review of Pharmacogenetics of ABC and SLC Transporter Genes in Acute Myeloid Leukemia

Review. 10.3390/pharmaceutics14040878. 2022

The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity

Garcia-Robles, Ana; (...); Saenz Gonzalez, Pilar

Article. 10.1007/s00431-022-04628-z. 2022

The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.

Gil-Nagel A; (...); Gil A

Article. 10.1016/j.yebeh.2022.108711. 2022

The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).

Badia, Xavier; (...); Valles, Joan-Antoni

Article. 10.1186/s13023-024-03324-5. 2024

The view of experts on initiatives to be undertaken to promote equity in the access to orphan drugs and specialised care for rare diseases in Spain: A Delphi consensus

Torrent-Farnell, J; (...); Lizan, L

Article. 10.1016/j.healthpol.2018.03.002. 2018

Topiramate pharmacokinetics in neonates undergoing therapeutic hypothermia and proposal of an optimised dosing schedule.

Marques MR; (...); Mangas-Sanjuan V

Article. 10.1111/apa.14944. 2020

Topiramate plus Cooling for Hypoxic-Ischemic Encephalopathy: A Randomized, Controlled, Multicenter, Double-Blinded Trial

Nunez-Ramiro, A; (...); Hypotop Study Grp

Article. 10.1159/000499084. 2019

Towards a symbiotic relationship between big data, artificial intelligence, and hospital pharmacy

Del Rio-Bermudez, C; (...); Poveda, JL

Editorial Material. 10.1186/s40545-020-00276-6. 2020

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.

Martínez-Cuadrón D; (...); Montesinos P

Article. 10.1182/bloodadvances.2021005335. 2022

Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?